BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9528719)

  • 1. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients.
    Keiser P; Rademacher S; Smith JW; Skiest D; Vadde V
    Am J Med; 1998 Jan; 104(1):48-55. PubMed ID: 9528719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus.
    Ambati BK; Perlman DC; Salomon N
    Int J Infect Dis; 1998-1999 Winter; 3(2):70-5. PubMed ID: 10225983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection.
    Keiser P; Rademacher S; Smith J; Skiest D
    Int J STD AIDS; 1998 Jul; 9(7):394-9. PubMed ID: 9696194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis.
    Davidson M; Min YI; Holbrook JT; Van Natta ML; Murphy R; Jabs DA; Welch W; Meinert CL;
    AIDS; 2002 Mar; 16(5):757-65. PubMed ID: 11964532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia.
    Kocherlakota P; La Gamma EF
    Pediatrics; 1997 Jul; 100(1):E6. PubMed ID: 9200380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
    Babalola CP; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2004 Jun; 53(6):1098-100. PubMed ID: 15128727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
    Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH
    Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
    Yoshida M; Karasawa M; Naruse T; Fukuda M; Hirashima K; Oh H; Ninomiya H; Abe T; Saito K; Shishido H; Moriyama Y; Shibata A; Motoyoshi K; Nagata N; Miura Y
    Int J Hematol; 1999 Feb; 69(2):81-8. PubMed ID: 10071455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of Filgrastim in AIDS-related neutropenia.
    Welch W; Foote M
    J Hematother Stem Cell Res; 1999; 8 Suppl 1():S9-16. PubMed ID: 10596030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients.
    Gruson D; Hilbert G; Vargas F; Valentino R; Chene G; Boiron JM; Reiffers J; Gbikpi-Benissan G; Cardinaud JP
    Crit Care Med; 2000 Sep; 28(9):3155-60. PubMed ID: 11008974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia.
    Bilgin K; Yaramiş A; Haspolat K; Taş MA; Günbey S; Derman O
    Pediatrics; 2001 Jan; 107(1):36-41. PubMed ID: 11134431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
    Kapogiannis BG; Soe MM; Nesheim SR; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2008 May; 121(5):e1229-39. PubMed ID: 18450865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
    Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
    J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.